Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Mustang Bio Inc Market Cap
Based on ratings from 1 stock analysts, the Mustang Bio Inc stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for Mustang Bio Inc. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.
MBIO is a stock in Healthcare which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from Oppenheimer and on the lower end MBIO is forecasted to be $ by from Oppenheimer.
These are the latest 20 analyst ratings of MBIO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $2 | Reiterates | May 16, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $2 | Maintains | May 13, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $18 | Reiterates | Aug 24, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $25 | Reiterates | Aug 16, 2023 |
| Justin Zelin BTIG | Buy | $16 | Maintains | Aug 15, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $25 | Reiterates | Aug 15, 2023 |
| Justin Zelin BTIG | Buy | $20 | Maintains | Jun 16, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $25 | Reiterates | Jun 16, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | May 15, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Mar 30, 2023 |
| Justin Zelin BTIG | Buy | $4 | Maintains | Nov 16, 2022 |
| Mayank Mamtani B. Riley Securities | Buy | $6 | Maintains | Jan 24, 2022 |
BTIG | Buy | Initiates | May 18, 2021 | |
B. Riley FBR | Buy | Initiates | Oct 2, 2020 | |
B. Riley Securities | Buy | Initiates | Oct 2, 2020 | |
Oppenheimer | Outperform | $13 | Maintains | May 12, 2020 |
HC Wainwright & Co. | Buy | Initiates | Aug 13, 2019 | |
H.C. Wainwright | Buy | Initiates | Aug 13, 2019 | |
Cantor Fitzgerald | Overweight | Initiates | Jun 21, 2019 | |
Oppenheimer | Outperform | Initiates | Dec 21, 2017 |
When did it IPO
2017
Staff Count
80
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Manuel Litchman M.D.
Market Cap
$9.2M
In 2023, MBIO generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MBIO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Mustang Bio, Inc. received an extension from the Nasdaq Hearings Panel to meet compliance criteria for continued listing on Nasdaq, with deadlines set for January 31 and February 18, 2025.
Why It Matters - Mustang Bio’s extension from Nasdaq suggests ongoing financial challenges, impacting its stock price and investor confidence. The outcome will influence market perception and investment decisions.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MB-108, an HSV-1 oncolytic virus, shows activity and good tolerance in patients with recurrent glioblastoma in a Phase 1 clinical trial.
Why It Matters - Positive Phase 1 trial results for MB-108 suggest potential for effective glioblastoma treatment, which could boost the biotechnology company's valuation and attract investor interest.
Thu, 24 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Mustang Bio, Inc. has agreed to exercise warrants for 16,877,638 shares at $0.237 each, expected to generate about $4 million in gross proceeds. Shares are registered under Form S-1.
Why It Matters - Mustang Bio's agreement to exercise warrants will generate around $4 million, enhancing its financial position and potentially funding further development in cell therapies, impacting investor confidence.
Fri, 28 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Diamond Equity Research published an update on Enveric Biosciences Inc. (NASDAQ: ENVB), detailing management insights, recent developments, outlook, and associated risks.
Why It Matters - The update from Diamond Equity Research on Enveric Biosciences Inc. provides insights into management strategies and market risks, influencing investor sentiment and potential stock performance.
Thu, 20 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Mustang Bio, Inc. announced a registered direct offering of 6.13 million shares at $0.41 each, alongside unregistered warrants for the same amount. The deal is expected to close by June 21, 2024.
Why It Matters - Mustang Bio's stock sale could dilute existing shares, impacting share value. The funding may support development efforts, influencing future growth potential and investor sentiment.
Fri, 21 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Mustang Bio, Inc. closed a registered direct offering, selling 6.13 million shares at $0.41 each. It also issued unregistered warrants for the same number of shares, exercisable for five years post-approval.
Why It Matters - Mustang Bio's direct offering and concurrent private placement raise capital, signaling potential growth or upcoming projects. The issuance of warrants may indicate investor interest but also dilutes existing shares.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
